

Integral Diagnostics Limited

2025 Annual General Meeting – Managing Director & Chief Executive Officer

Address and Presentation

Thank you, Toby, and good morning everyone. It's good to see you all, in the room and online.

Vision and Values

Our vision – to build a healthier world – is anchored in our six values: Patients First, Medical Leadership, One Team, Create Value, Integrity and Excellence, and Embrace Change. These values shape our decisions daily. From recruitment to performance evaluation, from capital allocation to clinical governance, our values ensure that patient care remains at the heart of everything we do.

Our values define us as healthcare professionals and caregivers. These values differentiate our company, even amongst our healthcare peers. Our values build our culture, our commitment to always practice good medicine, and our patient first ethos. We know that by putting our patients first, we will also be putting our shareholders first.

IDX Today

We completed our merger with Capitol Health in December last year and we are now 'One Team'. The merger could not have progressed better, from a clinical, cultural and financial perspective. Our teleradiology arm, IDXt, has provided significant support to Capitol's clinics since October 2024, reducing turnaround time and expediting patient care, alleviating bottlenecks, and retaining referrer goodwill. Best practices and policies have been evaluated across both groups and the best practice has been adopted. Employee and referrer engagement, in both groups, has remained strong or strengthened.

The combined IDX and Capitol served 1.8m patients over the past financial year, performed more than 4m examinations, and helped more than 80,000 referring doctors to reach a diagnosis. Our 3,025 employees, including doctors and staff, delivered exemplary patient care at 145 clinics in Australia and New Zealand.

We are now the second largest radiology network in Australia and the only pure-play listed DI provider in Australia. Scale matters in this business. Larger providers are able to adopt new technologies sooner, spread investment costs across a broader network, and attract top clinical talent.

I'd like to call out our teleradiology business unit, IDXt. IDXt provides genuine 24/7 reporting services to both our own network and to a growing list of external clients, including private practices, hospitals and regional health services.

IDXt, has continued its rapid growth trajectory over the past year. The business unit currently engages 114 radiologists, and its reported revenue has grown consistently at a CAGR above 30%. The IDXt employee value proposition is compelling as it is able to provide radiologists with as much work as they want, in an area of their interest, at a time and place of their choosing.

FY25 Results Overview

We closed FY25 in a far stronger position than we began – significantly higher patient volumes and revenue, improved margins, materially improved EPS, greater operating free cash flow, and a stronger balance sheet.

The operating environment presented challenges in the first half of the financial year, including clinical skills shortages which were more acute in regional areas, and inflationary cost pressures. We effectively addressed many of these challenges in the second half, particularly through the increased use of teleradiology and AI, the adoption of technologies that optimised the patient care pathway, including e-referrals and online appointments, and the realisation of people, procurement and administrative synergies from the merger with Capitol.

For FY25, IDX delivered revenue and other income of \$628.0m, up 33.7% on the prior year. Operating EBITDA rose to \$126.5m, an increase of 38.3% with the EBITDA margin expanding to 20.1%, up 60 basis points on the prior corresponding period. Operating free cash flow improved to \$80.0m, up 42.9%, and reflected disciplined capital expenditure and effective working capital management.

Net debt to EBITDA reduced to 2.6x (or 2.4x pro forma including annualised merger synergies), down from 2.8x at 31 December 2024.

Growth was driven by increased volumes across higher-value modalities, particularly PET-CT and MRI, continued expansion in teleradiology, and efficiency gains from procurement and process improvements implemented in the latter part of FY25.

PET-CT continues to be our fastest-growing modality, reflecting its importance in oncology, neurology and other specialities. We remain disciplined in our capital allocation, ensuring that each investment meets strict return thresholds while enhancing patient care in areas of high demand.

FY25 Strategic Overview

In FY25 we delivered against our strategic goals.

Toby has touched upon the success of our merger with Capitol. We have implemented a new organisation structure to support our focus on patients and drive the business and our merged procurement function is driving cost savings above initial synergy projections. I'm particularly proud of the strong employee engagement scores recorded in annual July survey.

In relation to organic growth, we have continued to drive this and focus on operational efficiencies. Radiologist recruitment, both on the ground and in our market-leading teleradiologist business, IDXt continues to be a strategic focus in a very tight recruitment market.

During the financial year, we opened five new greenfield clinics, including Spotswood in Victoria, Glenorchy in Tasmania and Noosa in Queensland.

We also relocated two clinics to new state of the art facilities; Ocean Grove in Victoria and the Smith Street Nuclear Medicine & Women's Imaging Centre in Southport, Queensland.

Consolidation continues in our DI sector, and IDX will rigorously evaluate additional M&A opportunities as they arise.

Industry Fundamentals

IDX is well positioned to improve access and benefits for patients and capitalise on positive industry fundamentals.

Demand for diagnostic imaging is supported by strong demographic drivers (ageing populations and the rising incidence of chronic disease) and by the expansion of medical expertise and treatment options that depend on accurate diagnostic imaging. Globally, diagnostic imaging advances in both hardware (e.g. faster CT, higher-resolution MRI, digital PET) and software (AI-enabled image analysis, secure digital platforms) are enabling more accurate diagnosis, faster turnaround times, and better patient experiences.

Medicare announced indexation of 2.4% for diagnostic imaging services commencing on 1 July 2025.

From 1 July 2025, all radiology clinics with an MRI licence (full or partial) received full Medicare eligibility for all MRIs at that clinic. IDX received 16 new full licences that were automatically upgraded from partial licences on 1 July 2025 (10 from previous Capitol sites and 6 from original IDX sites). A full MRI licence provides a clinic with the ability to service specialist MRI referrals as well as GPs.

As at today, IDX holds 42 fully licenced MRIs and 22 unlicensed MRIs in Australia which compares to the 17 full MRI licences we held at 30 June 2024.

From 1 July 2025, the Health Department launched the National Lung Cancer Screening Program (NLCSP). The NLCSP is a screening program using low-dose computed tomography (low-dose CT) scans to look for lung cancer in smokers between 50 and 70 years old without any symptoms. It aims to find lung cancer early and save lives. IDX has introduced an IDX-wide program called "Chest Scan" to provide patients with easier access to this life-saving program.

The expansion of GP Bulk Billing Practice Incentive Program to all Australians, effective 1 November 2025, will drive increased GP visits and increase radiology referrals. The Benefits are higher in regional areas (2 to 3 times urban rates) which will be a positive for our regional clinic network.

Recovery of DI Growth Rates in Line with Long Term Trends

Industry growth rates, on a 12-month rolling basis, have recovered to be in line with long term trends, driven by Medicare indexation, modality mix shift and structural demographic trends.

The top line on the chart represents Medicare benefits paid to DI providers, the bottom line on the chart represents the number of tests that were performed. The two lines are diverging due to the higher rate of increase in high acuity, high value tests like CT, MRI and PET-CT, relative to lower acuity tests, like basic XRay and ultrasound.

MRI deregulation and the National Lung Cancer Screening Program is expected to drive further growth in the near-to-medium-term.

The National Lung Cancer Screening Program is driving growth in screening CTs and follow up growth in interventional and PET-CTs. The Health Department has committed \$264m to the screening program over the four-year forward estimates.

FY26 Strategy and Priorities

Our priorities for FY26 are clear:

- Drive organic earnings growth, including relentless focus on radiologist recruitment and productivity, together with operational efficiency;
- Accelerate use of teleradiology, digital and AI to improve the patient and referrer experience and doctor efficiency;
- Drive our ESG strategy;
- Lead through our Values; and
- Complete IDX and Capitol merger integration, including ongoing realisation of additional synergies.

Outlook for FY26 and Beyond

IDX is a specialist, quality provider of diagnostic services and is well positioned to benefit from positive industry fundamentals, and to grow services strongly going forward.

The combined Group (IDX and Capitol) achieved 8.3% revenue growth in Australia YTD September vs p.c.p. on a like-for-like basis, compared to 9.4% Medicare benefits growth for the same period.

Revenue growth and Operating EBITDA margin is expected to expand further over time, with a projected Operating EBITDA margin of ~20% for 1H FY26 and ~21% for full year FY26, driven by:

- Inclusion of \$14.0m of annualised merger synergies.
- Ramp up of new greenfield clinics and brownfield investments.
- Scale benefits, including increased use of IDXt teleradiology, both internally and externally, together with procurement efficiencies.

- Seasonally stronger 2H organic Operating EBITDA performance (2H ~53% vs 1H ~47% in recent years). In FY26 the 2H weighting is expected to be more pronounced driven by the ramp up of further de-regulation of MRI's, the National Lung Cancer Screening Program and expansion from 1 November 2025 of the \$8B GP Bulk Billing Incentive Program to all Australians.

Group FY26 replacement and growth capex is expected to be between \$45.0m to \$55.0m (FY25: \$55.3m).

Appreciation

I will be retiring from IDX at the end of FY26 after what has been an extraordinary journey. I joined IDX when it was a regional radiology practice in 2017, and over the course of the next eight years we built Australasia's second largest radiology network, owning and operating clinics in every state of Australia and in the greater Auckland region of New Zealand. This remarkable journey has only been made possible by the extraordinary team I have had the privilege of working with, a team that is dedicated to delivering the best health outcome for every patient we serve.

In April 2017, the month prior to my commencement at IDX, our share price averaged \$1.25 and our total market capitalisation was \$180m. Today our share price is \$2.48 and our market capitalisation is \$955m. Over that period, we have declared \$142.7m in dividends. And even more importantly, we have positively impacted the health and the lives of millions of Australians and New Zealanders.

Today, your company is in excellent shape, ideally positioned to capitalise on the strong industry fundamentals, favourable demographic tailwinds and awesome new capabilities in diagnostic radiology and AI. IDX's people, our scale, clinical expertise, and technological capabilities, are truly world class. I remain excited about the company's prospects.

In closing my address, I'd like to thank our frontline healthcare heroes at IDX who continue to put our patients first every day. Our doctors and staff include some of the finest healthcare professionals in the world. Their professionalism and dedication, and their commitment to our patients and referrers, is inspiring.

My thanks also to our patients who put their trust in us, to our loyal referrers who trust their patients to us, and to you, our shareholders, who put your faith in us.

My sincere thanks to Toby Hall, our Chair, and to the IDX Board and management team, for their valuable counsel, insight, commitment and support.

Good medicine is still good business.

Dr Ian Kadish

Managing Director & Chief Executive Officer

MANAGING DIRECTOR & CEO PRESENTATION

Dr Ian Kadish



VISION, VALUES AND PURPOSE

OUR
VISION
a healthier world



OUR
PURPOSE
deliver the best health
outcomes for our patients



patients first
Patients are at the heart of
everything we do



medical leadership
Pursuing excellence in medical leadership
through evidence-based care



one team
Our united team is our greatest asset



create value
We deliver sustainable value to
all stakeholders



integrity & excellence
Working with honesty and transparency,
excelling beyond expectations



embrace change
Have the courage to change,
challenge and innovate



IDX TODAY – GROUP OVERVIEW AS AT 30 JUNE 2025

	      	 	  	 	 		   	
Geographic Market	Victoria	New South Wales	Queensland	Western Australia	Tasmania	South Australia	New Zealand	
Core markets	Metro and outer Western Melbourne, Geelong, Ballarat, Warrnambool, Mildura, Wangaratta, Wodonga, Yarrawonga	Albury, Lavington, Tweed Heads	Sunshine Coast, Rockhampton, Gladstone, Gold Coast, Toowoomba, Mackay, Brisbane	Metro Perth, South West Western Australia	Hobart, Launceston	Adelaide	Auckland	Total
Sites	63	3	41	12	5	1	20	145
Comprehensive sites ⁽¹⁾	30	1	17	4	3	1	5	61
MRI machines	35	1	17	4	3	1	6	67
MRI Licences ⁽⁵⁾	8 full 10 partial	1 full 0 partial	9 full 6 partial	2 full 0 partial	3 full 0 partial	0 full 0 partial	N/A	23 full 16 partial
PET Scanners	2	–	3	1	–	–	2	8
Employed Radiologists ⁽²⁾	76	0 ⁽⁶⁾	67	16	13	0	36 ⁽³⁾	208
Number of Employees	1,136	0 ⁽⁶⁾	940	311	120	23	249	2,779 ⁽⁴⁾

Notes:

Notes (1) to (6) referred to in the slide are set out on Slide 20

FY25 RESULTS OVERVIEW

Consolidated Group (AUD \$m)	FY25	vs FY24
Revenue ⁽¹⁾	628.0	↑ 33.7%
Operating EBITDA ⁽²⁾	126.5	↑ 38.3%
Operating EBITDA margin	20.1%	↑ 0.6%
Operating NPAT ⁽²⁾	31.6	↑ 74.4%
Statutory NPAT	4.8	n.m.
Operating Diluted EPS (cps)	10.2	↑ 32.9%
Final Dividend Per Share (cps)	4.0	↑ 21.2%
Operating free cash flow	80.0	↑ 42.9%
Net debt (pre-AASB 16)	298.0	
Net debt / pro forma EBITDA (pre-AASB 16) ⁽³⁾⁽⁴⁾	2.6x	
Net debt / pro forma EBITDA (pre-AASB 16) inclusive of annualised synergies of \$14.0m ⁽³⁾	2.4x	

Notes:

Notes (1) to (5) referred to in the slide are set out on Slide 20

1

Solid revenue growth of 33.7% to \$628.0m (including ~6-months contribution from Capitol Health post-merger)
(6.7% growth on an IDX standalone basis)

2

Improved operating EBITDA margin of 20.1% (up 0.6% vs FY24)

3

Strong growth in Operating Diluted EPS and Final Dividend per Share of 32.9% and 21.2% respectively

4

Capitol merger synergies materially above expectation; now expecting \$14.0m annualised (\$7.0m realised in FY25)
(vs at least \$10.0m of annualised synergies expected previously)

5

Strong balance sheet with reduced leverage of 2.6x at 30 June 2025 (2.4x including pro forma annualised synergies of \$14.0m)

6

Already realising strategic benefits from Capitol merger across teleradiology, procurement and employee engagement, with further benefits to come

7

Well positioned to further capitalise on industry tailwinds to drive strong revenue growth and further margin expansion
(MRI de-regulation, National Lung Cancer Screening Program and GP Bulk Billing Practice Incentive Program)

8

Delivering better clinical outcomes for our patients (NPS of 82⁽⁵⁾) and referrers, with strong radiologist engagement

FY25 STRATEGIC OVERVIEW – KEY PROGRESS UPDATE

Capitol merger



Proceeding on plan with synergies to exceed initial expectations and strategic benefits already being realised

- New organisation structure implemented to support focus on patients and drive the business.
- Annualised ongoing synergies now expected to be \$14.0m (compared to at least \$10.0m expected previously), with \$7.0m realised in FY25.
- Procurement function established and driving cost savings above initial synergy projections.
- Increased teleradiology scale with contribution from Capitol radiologists.
- Strong employee engagement scores recorded in annual July survey.

LFL organic growth



Ongoing focus on driving organic growth and operational efficiencies

- Continued strategic focus on radiologist recruitment, productivity and efficiency to support growing demand for services by patients.
- Enhanced focus on teleradiologist recruitment to grow IDX's industry leading teleradiology platform IDXt, to drive further operational efficiency and margin improvement.
- IDXt now has 114 teleradiologists at 30 June 2025 (up from 93 at 31 December 2024 and 80 at 30 June 2024).
- Continued focus on delivering additional operating expense and capex savings.

Greenfield and inorganic growth



Continued evaluation and implementation of incremental greenfield and inorganic growth initiatives


- Five new greenfield clinics opened in FY25.
 - Spotswood, Glenorchy, Noosa.
 - Relocation to new state of the art facilities for Ocean Grove and Smith Street Nuclear Medicine & Women's Imaging Centre.
- Rigorous evaluation of additional M&A opportunities to be considered as opportunities arise and industry consolidation continues.

IDX WELL POSITIONED TO IMPROVE ACCESS AND BENEFITS FOR PATIENTS & CAPITALISE ON POSITIVE INDUSTRY FUNDAMENTALS


- ✓ Ageing population and earlier detection of disease drive demand for diagnostic services.
- ✓ Medicare DI benefits and services have recovered to be in line with long term trends.
- ✓ Medicare indexation of 2.4% for FY26.
- ✓ Structural shift to higher value modalities.
 - Upgrade to full licences of partially licenced MRIs effective 1 July 2025 and for all MRIs from 1 July 2027 to drive further growth in MRI.
 - As at today, IDX holds 42 fully licenced MRIs and 22 unlicensed MRIs in Australia.¹
 - National Lung Cancer Screening Program launched on 1 July 2025 driving growth in screening CTs and follow up growth in interventional CT and PET-CTs.
 - Health Department has committed \$264m to the screening program over the four year forward estimates.
- ✓ Technological advancements including teleradiology (~15% of scans) and AI (~10% of scans) enhancing quality of care and improving labour productivity.
- ✓ Proposed expansion of GP Bulk Billing Practice Incentive Program to all Australians, effective 1 November 2025, which will drive increased GP visits and increase radiology referrals.
 - Benefits higher in regional areas (2 to 3 times urban rates).
- ✓ Expedited specialist pathway for radiologists from the UK and Ireland expected to be implemented later this calendar year (administered by the Medical Board of Australia and AHPRA).
- ✓ Government pledge of new funds for 400 nursing scholarships by 2027 and 2,000 more GP trainees by 2028.

Notes:

1. As at 31 October 2025. Comprises 23 fully licenced MRIs plus 16 partially licensed MRIs (now fully licensed) at 30 June 2025 plus 3 MRIs at licenced sites which became fully licenced from 1 July 2025



DI GROWTH RATES HAVE RECOVERED TO BE IN LINE WITH LONG TERM TRENDS: AUSTRALIA



Industry growth rates, on a 12-month rolling basis, have recovered to be in line with long term trends, driven by Medicare indexation, modality mix shift and structural demographic trends.

MRI deregulation and the National Lung Cancer Screening Program is expected to drive further growth in the near-to-medium-term.

FY26 STRATEGY AND PRIORITIES

Strategy	1	Grow Existing Business and Margin				2	Strategic Mergers & Acquisitions
Drivers of Strategy in FY26 and Beyond	Drive organic earnings growth, including relentless focus on radiologist recruitment and productivity, together with operational efficiency	Accelerate use of teleradiology, digital and AI to improve the patient and referrer experience and doctor efficiency	Drive our environmental, social and governance (ESG) strategy	Lead through our Values	Complete IDX and Capitol Health merger integration, including ongoing realisation of additional synergies		

OUTLOOK FOR FY26 AND BEYOND

- IDX is a specialist, quality provider of diagnostic services and is well positioned to benefit from positive industry fundamentals, and to grow services strongly going forward.
- The combined Group (IDX and Capitol) achieved 8.3% revenue growth in Australia YTD September vs p.c.p. on a like-for-like basis¹, compared to 9.4% Medicare benefits growth for the same period.
- Revenue growth and Operating EBITDA margin is expected to expand further over time, with a projected Operating EBITDA margin of ~20% for 1H FY26 and ~21% for full year FY26, driven by:
 - Inclusion of \$14.0m of annualised merger synergies.
 - Ramp up of new greenfield clinics and brownfield investments.
 - Scale benefits, including increased use of IDXt teleradiology, both internally and externally, together with procurement efficiencies.
 - Seasonally stronger 2H organic Operating EBITDA performance (2H ~53% vs 1H ~47% in recent years)².
 - In FY26 the 2H weighting is expected to be more pronounced driven by the ramp up of further de-regulation of MRI's, the National Lung Cancer Screening Program and expansion from 1 November 2025 of the \$8B GP Bulk Billing Incentive Program to all Australians.
- Group FY26 replacement and growth capex is expected to be between \$45.0m to \$55.0m (FY25: \$55.3m).

Notes:

1. Adjusted for four closed clinics and the sale of the Melton clinic
2. FY23 to FY25, with FY25 adjusted to exclude 2.0% reduction in CT Medicare funding from 1 November 2024

NOTES TO SLIDES

Slide 13: IDX Today – Group Overview

1. Comprehensive sites include a range of radiology equipment including MRI's and CT's and are located with or near major specialist referrers.
2. Relates to employed radiologists only. In addition, IDX has 251 contractor radiologists providing services.
3. Consistent with the NZ private radiology model, all doctors work across the public and private sector and meet the criteria to be classified as contractors but are on terms and conditions similar to IDX employed radiologists.
4. This number represents staff on employment contracts (either part-time or full-time). It does not represent the number of full-time equivalent employees or individual casual/contract arrangements. In addition, there are 246 employees in the corporate offices (including IDXt) totalling 3,025 employees.

5. Of the 67 MRI machines, 61 are located in Australia with 45 located in MM1 areas, including 16 partially licenced machines and 3 unlicenced machines (both of which become fully licenced machines effective 1 July 2025), and 16 located in MM2-7 areas.
6. NSW staff are included in the Victorian and Queensland numbers noting staff move across sites and local regions.

Slide 14: FY25 Results Overview

1. FY25 revenue includes income recognised of \$0.8m relating to expected recoveries from an insurance claim for the impact of Tropical Cyclone Alfred in South-east Queensland in March 2025, reflecting revenue that would otherwise have been earned.
2. Non-operating transactions not included in operating metrics include the impact of impairment losses, transaction and integration costs, restructuring costs, remeasurement of contingent consideration liabilities, amortisation of customer contracts and share based payments to doctors, net of tax, of \$26.8m (FY24: \$78.8m).

3. The impact of AASB 16: Leases on FY25 results was an increment to pro forma Operating EBITDA of \$27.8m, an increment to pro forma Operating EBITA of \$5.4m and a decrement to pro forma Operating NPAT of \$2.8m, using the approximate cash cost of these ongoing leases in making these adjustments. The impact of AASB 16: Leases on FY24 results was an increment to Operating EBITDA of \$20.5m, an increment to Operating EBITA of \$3.0m and a decrement to Operating NPAT of \$1.8m, using the approximate cash cost of these ongoing leases in making these adjustments.
4. FY25 net debt/pro forma EBITDA ratio is based on net debt at 30 June 2025 of \$298.0m and LTM Operating EBITDA (including trailing acquisitions EBITDA) of \$116.4m, excluding annualised synergies of \$14.0m (at least \$10.0m expected at 31 December 2024) following the merger with Capitol Health. FY24 is based on net debt at 30 June 2024 of \$183.5m and LTM Operating EBITDA (plus trailing EBITDA from acquisitions) of \$69.4m.
5. Represents IDX patient NPS scores in Australia.

DISCLAIMER

1. Some of the information contained in this presentation contains “forward-looking statements” which may not directly or exclusively relate to historical facts. These forward-looking statements reflect Integral Diagnostics Limited (IDX) current intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside the control of IDX.
2. Important factors that could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements include known and unknown risks. Because actual results could differ materially from IDX current intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained herein with caution.
3. Past performance of IDX cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of IDX.
4. To the maximum extent permitted by law, none of IDX, or its respective affiliates or related bodies corporate or any of their respective officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, IDX, the Group or IDX securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.
5. Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not a financial product or investment advice or recommendation to acquire IDX securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in IDX and should not rely on this presentation. In all cases, you should conduct your own research of IDX and the Group and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of IDX, the Group and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.